缓退瘤耐受的前列腺癌的抗雄激素治疗  

Androgen-deprivation Therapy for Flutamide Resistant Prostate Cancer

作　　者：李新德[1] 许力为[1] 余大敏[1] 张大宏[1] 芮雪芳[1] 李恭会[1] 

机构地区：[1]浙江大学医学院附属邵逸夫医院,浙江杭州310016

出　　处：《中国肿瘤》2005年第12期839-840,共2页China Cancer

摘　　要：[目的]探讨康士得对于缓退瘤耐受的前列腺癌的疗效。[方法]应用康士得治疗缓退瘤联合去势术难控制前列腺癌患者11例。[结果]11例患者中6例康士得治疗有效,有效率54.5%(6/11),血清前列腺特异性抗原(PSA)下降范围61%～99%,临床症状均有不同程度改善,治疗有效持续时间3～10个月,平均5.3个月。所有患者服用康士得耐受性良好。[结论]缓退瘤联合去势术难控制前列腺癌患者可考虑改用康士得继续抗雄激素治疗。[Purpose] To investigate the effect of bicalutamide for flutamide resistant prostate cancer. [Method]Eleven patients with flutamide resistance were treated with Bicalutamide. [Results ] Six cases （6/11） responsed to Bicalutamide （response rate 54.5%, response duration 3-10 months, mean 5.3 months） who demonstrated PSA declines of 61%-99% and improvement in clinical performance. Bicalutamide was well tolerated. [ Conclusion ] Bicalutamide was effective for patients with flutamide resistant prostate cancer. Key words： prostate neoplasms; androgen; androgen antagonist

关 键 词：前列腺肿瘤 雄激素 雄激素拈抗药 

分 类 号：R737.25[医药卫生—肿瘤]